Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Canagliflozin | Selegiline | |
|---|---|---|
| Category | Pharmaceuticals | Pharmaceuticals |
| Standard Dose | — | — |
| Timing | — | — |
| Cycle Duration | — | — |
| Evidence Level | Moderate (longevity), Strong (cardiorenal) | Strong |
SGLT2 inhibitor originally developed for type 2 diabetes. Blocks glucose reabsorption in kidneys, creating a mild glucose deficit that activates AMPK and mimics caloric restriction. Extended lifespan in male mice in the ITP.
Selective MAO-B inhibitor that raises dopaminergic tone at lower doses and is used clinically in Parkinson's disease and select mood protocols.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →